Erasca, Inc. (ERAS)
16.87
-1.01
(-5.65%)
USD |
NASDAQ |
Sep 01, 14:29
Erasca Research and Development Expense (Annual) : 92.85M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 92.85M |
| December 31, 2024 | 112.41M |
| December 31, 2023 | 103.82M |
| December 31, 2022 | 214.46M |
| Date | Value |
|---|---|
| December 31, 2021 | 84.77M |
| December 31, 2020 | 101.30M |
| December 31, 2019 | 9.618M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Revolution Medicines, Inc. | 978.68M |
| Tango Therapeutics, Inc. | 129.88M |
| Cogent Biosciences, Inc. | 265.16M |
| Apogee Therapeutics, Inc. | 214.42M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |